Q702

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
46 patients (estimated)
Sponsors
Mayo Clinic
Tags
CSF1R Inhibitor, AXL Inhibitor, MER Inhibitor
Trial Type
Treatment
Last Update
SparkCures ID
2034
NCT Identifier
NCT06712810

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.